Becton, Dickinson and Company $BDX Shares Acquired by Stonebridge Financial Group LLC

Key Points

• Stonebridge Financial Group LLC has increased its stake in Becton, Dickinson and Company (BDX) by 16.2%, now owning 18,877 shares worth approximately $3.25 million.
• Becton, Dickinson and Company reported a quarterly earnings per share (EPS) of $3.68, surpassing estimates, and anticipates an FY 2025 EPS between $14.300 and $14.450.
• The company announced a quarterly dividend of $1.04 per share, yielding 2.2%, with a current payout ratio of 74.82%.

Stonebridge Financial Group LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 16.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,877 shares of the medical instruments supplier's stock after purchasing an additional 2,629 shares during the quarter. Stonebridge Financial Group LLC's holdings in Becton, Dickinson and Company were worth $3,251,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after purchasing an additional 1,259,750 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 3.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after purchasing an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after buying an additional 667,957 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Becton, Dickinson and Company by 7.6% during the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock worth $1,012,649,000 after buying an additional 312,124 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock worth $707,872,000 after buying an additional 37,733 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Down 2.5%

Shares of Becton, Dickinson and Company stock opened at $189.06 on Friday. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The business's fifty day moving average is $189.87 and its two-hundred day moving average is $186.61. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market cap of $54.19 billion, a PE ratio of 34.00, a P/E/G ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the firm posted $3.50 earnings per share. The business's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock valued at $562,036 in the last ninety days. 0.36% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BDX. Argus lifted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Royal Bank Of Canada began coverage on Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a "sector perform" rating and a $211.00 price objective for the company. Weiss Ratings reiterated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a report on Wednesday. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.